
Breast Lesion Localization Methods Market Report and Forecast 2025-2034
Description
The global breast lesion localization methods market size was valued at USD 292.08 Million in 2024, driven by the emphasis on preventing the increasing cases of breast cancer across the globe. The market is expected to grow at a CAGR of 4.80% during the forecast period of 2025-2034, with the values likely to rise from USD 466.78 Million by 2034.
Breast Lesion Localization Methods: Introduction
A breast lesion refers to the presence of an abnormal tissue or lump in the breast area. It can be a single or cluster of lumps. Although most lesions are benign (non-cancerous), some might turn out to be malignant (cancerous), hence, early detection is highly imperative. Symptoms for benign breast lesion may include pain in the affected area, fatigue, discomfort or loss of weight and appetite. Whereas changes in breast size, swelling or hardened area inside the underarm or breast are common indicators of malignant breast lesions.
Locating these lesions is extremely crucial in order to get a timely treatment. A breast lesion can be found through a self or clinical exam, which can be later confirmed using an imaging test. Diagnostic methods commonly constitute mammograms, magnetic resonance imaging (MRI), computed tomography (CT) scans, and ultrasounds.
Breast Lesion Localization Methods Market Analysis
With the rising prevalence of breast cancer, the number of surgeries has been on a rise. When compared to mastectomy, the frequency of breast-conserving (lumpectomy) surgery is higher. This is because it only removes the area of tumour and allows faster recovery as well. Since, these tumours are non-palpable, they require localization, which can be done through an ultrasound or mammography. As a result, the breast lesion localization methods market value has increased over the years.
Over the years, wire guided localization (WGL) has been commonly used for the surgical excision of a non-palpable breast lesion. This can be accredited to its low cost, high efficacy, and ease of accessibility. However, owing to several logistical challenges like its placement, patient discomfort and a possibility of wire dislocation, breast surgeons have showed their preference for other techniques like radioactive seed localization, radio-occult lesion localization (ROLL), and intraoperative ultrasound. As a result, the market for breast lesion localization has been evolving and welcoming new developments.
New localization devices like SAVI SCOUT®, Localizer™, Molli™, Magseed®, EnVisio®, and Pintuition® have flourished the market. MELODY (Methods for Localization of Different types of breast lesions) is another initiative launched by the European Breast Cancer Research Association of Surgical Trialists and the iBRA-NET. It allows the study of breast localization techniques and devices from various perspectives by enrolling a cohort of breast cancer patients, undergoing breast-conserving surgery using imaging-guided localization. Such initiatives indicate that we can observe breast lesion localization methods market growth in the upcoming years.
Breast Lesion Localization Methods Market Segmentation
Breast Lesion Localization Methods Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Product Type
The occurrence of breast cancer has been more common than lung cancer. Approximately, 297,790 women in the United States alone are estimated to be diagnosed with lung cancer in 2024. As a result, Unites States holds the largest breast lesion localization methods market share. With a high-tech infrastructure and the presence of major universities and healthcare industry pioneers, there has been significant emphasis on bringing quality diagnostics and treatments for the patients. Moreover, WHO recently released a Global Breast Cancer Initiative Framework that provides a roadmap to save around 2.5 million lives from breast cancer by 2040.
In addition, India partnered with the United States to develop an artificial intelligence (AI)-enabled digital pathology platform that will enable better diagnosis and prediction of therapeutic benefits to the patients. The US-India cancer dialogue also aims to bring the public and private sector that envisions around data sharing and synthetic biology.
Breast Lesion Localization Methods Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Breast Lesion Localization Methods: Introduction
A breast lesion refers to the presence of an abnormal tissue or lump in the breast area. It can be a single or cluster of lumps. Although most lesions are benign (non-cancerous), some might turn out to be malignant (cancerous), hence, early detection is highly imperative. Symptoms for benign breast lesion may include pain in the affected area, fatigue, discomfort or loss of weight and appetite. Whereas changes in breast size, swelling or hardened area inside the underarm or breast are common indicators of malignant breast lesions.
Locating these lesions is extremely crucial in order to get a timely treatment. A breast lesion can be found through a self or clinical exam, which can be later confirmed using an imaging test. Diagnostic methods commonly constitute mammograms, magnetic resonance imaging (MRI), computed tomography (CT) scans, and ultrasounds.
Breast Lesion Localization Methods Market Analysis
With the rising prevalence of breast cancer, the number of surgeries has been on a rise. When compared to mastectomy, the frequency of breast-conserving (lumpectomy) surgery is higher. This is because it only removes the area of tumour and allows faster recovery as well. Since, these tumours are non-palpable, they require localization, which can be done through an ultrasound or mammography. As a result, the breast lesion localization methods market value has increased over the years.
Over the years, wire guided localization (WGL) has been commonly used for the surgical excision of a non-palpable breast lesion. This can be accredited to its low cost, high efficacy, and ease of accessibility. However, owing to several logistical challenges like its placement, patient discomfort and a possibility of wire dislocation, breast surgeons have showed their preference for other techniques like radioactive seed localization, radio-occult lesion localization (ROLL), and intraoperative ultrasound. As a result, the market for breast lesion localization has been evolving and welcoming new developments.
New localization devices like SAVI SCOUT®, Localizer™, Molli™, Magseed®, EnVisio®, and Pintuition® have flourished the market. MELODY (Methods for Localization of Different types of breast lesions) is another initiative launched by the European Breast Cancer Research Association of Surgical Trialists and the iBRA-NET. It allows the study of breast localization techniques and devices from various perspectives by enrolling a cohort of breast cancer patients, undergoing breast-conserving surgery using imaging-guided localization. Such initiatives indicate that we can observe breast lesion localization methods market growth in the upcoming years.
Breast Lesion Localization Methods Market Segmentation
Breast Lesion Localization Methods Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Product Type
- Localization Wires
- Radioactive Seeds
- Magnetic Tracers
- Others
- Wire Localization
- Radioactive Seed Localization
- Magnetic Tracers
- Others
- Diagnostic
- Therapeutic
- Diagnostic Centers
- Hospitals
- Oncology Clinics
- Ambulatory Surgical Centers
- Others
- United States
- EU-4 and the United Kingdom
- Japan
The occurrence of breast cancer has been more common than lung cancer. Approximately, 297,790 women in the United States alone are estimated to be diagnosed with lung cancer in 2024. As a result, Unites States holds the largest breast lesion localization methods market share. With a high-tech infrastructure and the presence of major universities and healthcare industry pioneers, there has been significant emphasis on bringing quality diagnostics and treatments for the patients. Moreover, WHO recently released a Global Breast Cancer Initiative Framework that provides a roadmap to save around 2.5 million lives from breast cancer by 2040.
In addition, India partnered with the United States to develop an artificial intelligence (AI)-enabled digital pathology platform that will enable better diagnosis and prediction of therapeutic benefits to the patients. The US-India cancer dialogue also aims to bring the public and private sector that envisions around data sharing and synthetic biology.
Breast Lesion Localization Methods Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Boston Scientific Corporation
- BD
- Medtronic
- Abbott
- Cook
- Stryker
- Wright Medical Group N.V.
- Zimmer Biomet
- Smith+Nephew
- Boston Scientific Corporation
- Organogenesis Inc.
- Arthrex, Inc.
- Orthofix Medical Inc.
- Kubtec X-Ray
- Miltenyi Biotec GMBH
- Naviscan
- PerkinElmer Inc.
- Thermo Fisher Scientific, Inc.
- Merit Medical Systems
Table of Contents
350 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Breast Lesion Localization Methods Market Overview
- 3.1 Breast Lesion Localization Methods Market Historical Value (2018-2024)
- 3.2 Breast Lesion Localization Methods Market Forecast Value (2025-2034)
- 4 Breast Lesion Localization Methods Market Landscape
- 4.1 Breast Lesion Localization Methods Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 Breast Lesion Localization Methods Product Landscape
- 4.2.1 Analysis by Product Type
- 4.2.2 Analysis by Type
- 4.2.3 Analysis by Applications
- 5 Breast Lesion Localization Methods Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.3 Porter’s Five Forces Model
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Breast Lesion Localization Methods Market Segmentation
- 6.1 Breast Lesion Localization Methods Market by Product Type
- 6.1.1 Market Overview
- 6.1.2 Localization Wires
- 6.1.3 Radioactive Seeds
- 6.1.4 Magnetic Tracers
- 6.1.5 Others
- 6.2 Breast Lesion Localization Methods Market by Technique
- 6.2.1 Market Overview
- 6.2.2 Wire Localization
- 6.2.3 Radioactive Seed Localization
- 6.2.4 Magnetic Tracers
- 6.2.5 Others
- 6.3 Breast Lesion Localization Methods Market by Application
- 6.3.1 Market Overview
- 6.3.2 Diagnostic
- 6.3.3 Therapeutic
- 6.4 Breast Lesion Localization Methods Market by End User
- 6.4.1 Market Overview
- 6.4.2 Diagnostic Centres
- 6.4.3 Hospitals
- 6.4.4 Oncology Clinics
- 6.4.5 Ambulatory Surgical Centres
- 6.4.6 Others
- 6.5 Breast Lesion Localization Methods Market by Region- 7MM
- 6.5.1 Market Overview
- 6.5.2 United States
- 6.5.3 EU-4 and the United Kingdom
- 6.5.4 Japan
- 7 United States Breast Lesion Localization Market
- 7.1 U.S. Breast Lesion Localization Market Historical Size (2018-2024)
- 7.2 U.S. Breast Lesion Localization Market Forecast Size (2025-2034)
- 7.3 Market Size by Therapeutic Class
- 8 EU-5 and the United Kingdom Breast Lesion Localization Market
- 8.1 EU-5 and the United Kingdom Breast Lesion Localization Market Historical Size (2018-2024)
- 8.2 EU-5 and the United Kingdom Breast Lesion Localization Market Forecast Size (2025-2034)
- 8.3 Market Size by Therapeutic Class
- 9 Japan Breast Lesion Localization Market
- 9.1 Japan Breast Lesion Localization Market Historical Size (2018-2024)
- 9.2 Japan Breast Lesion Localization Market Forecast Size (2025-2034)
- 9.3 Market Size by Therapeutic Class
- 10 Patent Analysis
- 10.1 Analysis by Type of Patent
- 10.2 Analysis by Publication year
- 10.3 Analysis by Issuing Authority
- 10.4 Analysis by Patent Age
- 10.5 Analysis by CPC Analysis
- 10.6 Analysis by Patent Valuation
- 10.7 Analysis by Key Players
- 11 Grants Analysis
- 11.1 Analysis by year
- 11.2 Analysis by Amount Awarded
- 11.3 Analysis by Issuing Authority
- 11.4 Analysis by Grant Application
- 11.5 Analysis by Funding Institute
- 11.6 Analysis by NIH Departments
- 11.7 Analysis by Recipient Organization
- 12 Funding Analysis
- 12.1 Analysis by Funding Instances
- 12.2 Analysis by Type of Funding
- 12.3 Analysis by Funding Amount
- 12.4 Analysis by Leading Players
- 12.5 Analysis by Leading Investors
- 12.6 Analysis by Geography
- 13 Partnership and Collaborations Analysis
- 13.1 Analysis by Partnership Instances
- 13.2 Analysis by Type of Partnership
- 13.3 Analysis by Leading Players
- 13.4 Analysis by Geography
- 14 Regulatory Framework
- 14.1 Regulatory Overview
- 14.1.1 US FDA
- 14.1.2 EU EMA
- 14.1.3 JAPAN PMDA
- 15 Supplier Landscape
- 15.1 Boston Scientific Corporation
- 15.1.1 Financial Analysis
- 15.1.2 Product Portfolio
- 15.1.3 Demographic Reach and Achievements
- 15.1.4 Mergers and Acquisition
- 15.1.5 Certifications
- 15.2 BD
- 15.2.1 Financial Analysis
- 15.2.2 Product Portfolio
- 15.2.3 Demographic Reach and Achievements
- 15.2.4 Mergers and Acquisition
- 15.2.5 Certifications
- 15.3 Medtronic
- 15.3.1 Financial Analysis
- 15.3.2 Product Portfolio
- 15.3.3 Demographic Reach and Achievements
- 15.3.4 Mergers and Acquisition
- 15.3.5 Certifications
- 15.4 Abbott
- 15.4.1 Financial Analysis
- 15.4.2 Product Portfolio
- 15.4.3 Demographic Reach and Achievements
- 15.4.4 Mergers and Acquisition
- 15.4.5 Certifications
- 15.5 Cook
- 15.5.1 Financial Analysis
- 15.5.2 Product Portfolio
- 15.5.3 Demographic Reach and Achievements
- 15.5.4 Mergers and Acquisition
- 15.5.5 Certifications
- 15.6 Stryker
- 15.6.1 Financial Analysis
- 15.6.2 Product Portfolio
- 15.6.3 Demographic Reach and Achievements
- 15.6.4 Mergers and Acquisition
- 15.6.5 Certifications
- 15.7 Wright Medical Group N.V.
- 15.7.1 Financial Analysis
- 15.7.2 Product Portfolio
- 15.7.3 Demographic Reach and Achievements
- 15.7.4 Mergers and Acquisition
- 15.7.5 Certifications
- 15.8 Zimmer Biomet
- 15.8.1 Financial Analysis
- 15.8.2 Product Portfolio
- 15.8.3 Demographic Reach and Achievements
- 15.8.4 Mergers and Acquisition
- 15.8.5 Certifications
- 15.9 Smith+Nephew
- 15.9.1 Financial Analysis
- 15.9.2 Product Portfolio
- 15.9.3 Demographic Reach and Achievements
- 15.9.4 Mergers and Acquisition
- 15.9.5 Certifications
- 15.10 Boston Scientific Corporation
- 15.10.1 Financial Analysis
- 15.10.2 Product Portfolio
- 15.10.3 Demographic Reach and Achievements
- 15.10.4 Mergers and Acquisition
- 15.10.5 Certifications
- 15.11 Organogenesis Inc.
- 15.11.1 Financial Analysis
- 15.11.2 Product Portfolio
- 15.11.3 Demographic Reach and Achievements
- 15.11.4 Mergers and Acquisition
- 15.11.5 Certifications
- 15.12 Arthrex, Inc.
- 15.12.1 Financial Analysis
- 15.12.2 Product Portfolio
- 15.12.3 Demographic Reach and Achievements
- 15.12.4 Mergers and Acquisition
- 15.12.5 Certifications
- 15.13 Orthofix Medical Inc.
- 15.13.1 Financial Analysis
- 15.13.2 Product Portfolio
- 15.13.3 Demographic Reach and Achievements
- 15.13.4 Mergers and Acquisition
- 15.13.5 Certifications
- 15.14 Kubtec X-Ray
- 15.14.1 Financial Analysis
- 15.14.2 Product Portfolio
- 15.14.3 Demographic Reach and Achievements
- 15.14.4 Mergers and Acquisition
- 15.14.5 Certifications
- 15.15 Miltenyi Biotec GMBH
- 15.15.1 Financial Analysis
- 15.15.2 Product Portfolio
- 15.15.3 Demographic Reach and Achievements
- 15.15.4 Mergers and Acquisition
- 15.15.5 Certifications
- 15.16 Naviscan
- 15.16.1 Financial Analysis
- 15.16.2 Product Portfolio
- 15.16.3 Demographic Reach and Achievements
- 15.16.4 Mergers and Acquisition
- 15.16.5 Certifications
- 15.17 PerkinElmer Inc.
- 15.17.1 Financial Analysis
- 15.17.2 Product Portfolio
- 15.17.3 Demographic Reach and Achievements
- 15.17.4 Mergers and Acquisition
- 15.17.5 Certifications
- 15.18 Thermo Fisher Scientific, Inc.
- 15.18.1 Financial Analysis
- 15.18.2 Product Portfolio
- 15.18.3 Demographic Reach and Achievements
- 15.18.4 Mergers and Acquisition
- 15.18.5 Certifications
- 15.19 Merit Medical Systems
- 15.19.1 Financial Analysis
- 15.19.2 Product Portfolio
- 15.19.3 Demographic Reach and Achievements
- 15.19.4 Mergers and Acquisition
- 15.19.5 Certifications
- 16 Breast Lesion Localization Methods Market - Distribution Model (Additional Insight)
- 16.1 Overview
- 16.2 Potential Distributors
- 16.3 Key Parameters for Distribution Partner Assessment
- 17 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 18 Company Competitiveness Analysis (Additional Insight)
- 18.1 Very Small Companies
- 18.2 Small Companies
- 18.3 Mid-Sized Companies
- 18.4 Large Companies
- 18.5 Very Large Companies
- 19 Payment Methods (Additional Insight)
- 19.1 Government Funded
- 19.2 Private Insurance
- 19.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.